Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

医学 苯拉唑马布 安慰剂 哮喘 内科学 临床试验 美波利祖马布 嗜酸性粒细胞 随机对照试验 病理 替代医学
作者
Mario Castro,James Zangrilli,Michael E. Wechsler,Eric D. Bateman,Guy Brusselle,Philip G. Bardin,Kevin Murphy,Jorge Máspero,Christopher O’Brien,Stephanie Korn
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:3 (5): 355-366 被引量:1179
标识
DOI:10.1016/s2213-2600(15)00042-9
摘要

Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations. Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death. We aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, moderate-to-severe asthma.We did two duplicate, multicentre, double-blind, parallel-group, randomised, placebo-controlled phase 3 trials. Both trials enrolled patients with asthma aged 12-75 years (from 128 clinical research centres in study 1 and 104 centres in study 2) from Asia, Australia, North America, South America, South Africa, and Europe, whose asthma was inadequately controlled by medium-to-high doses of inhaled corticosteroid based therapy and who had blood eosinophils of 400 cells per μL or higher and one or more exacerbations in the previous year. Patients were randomly assigned (1:1) to receive either intravenous reslizumab (3·0 mg/kg) or placebo every 4 weeks for 1 year by computerised central randomisation. Patients and investigators were masked to treatment assignment during the study. Each patient received a specific volume of study drug (reslizumab or matching placebo) on the basis of the patient's body weight and randomly assigned treatment group. Additionally, the sponsor's clinical personnel involved in the study were masked to the study drug identity until the database was locked for analysis and the treatment assignment revealed. The primary outcome was the annual frequency of clinical asthma exacerbations and was analysed by intention to treat. We assessed safety outcomes in the patients who had received one or more dose of the drug. The trials have been completed and are registered with ClinicalTrials.gov, numbers NCT01287039 (study 1) and NCT01285323 (study 2).Study 1 was done between April 12, 2011, and March 3, 2014 and study 2 between March 22, 2011, and April 9, 2014. Of 2597 patients screened, 953 were randomly assigned to receive either reslizumab (n=477 [245 in study 1 and 232 in study 2]) or placebo (n=476 [244 and 232]). In both studies, patients receiving reslizumab had a significant reduction in the frequency of asthma exacerbations (study 1: rate ratio [RR] 0·50 [95% CI 0·37-0·67]; study 2: 0·41 [0·28-0·59]; both p<0·0001) compared with those receiving placebo. Common adverse events on reslizumab were similar to placebo. The most common adverse events were worsening asthma symptoms (127 [52%] for placebo and 97 [40%] for reslizumab in study 1; 119 [51%] for placebo and 67 [29%] for reslizumab for study 2), upper respiratory tract infections (32 [13%] and 39 [16%]; 16 [7%] and eight [3%]), and nasopharyngitis (33 [14%] and 28 [11%]; 56 [24%] and 45 [19%]). Two patients in the reslizumab group had anaphylactic reactions; both responded to standard treatment at the study centre and resolved, and the patients were withdrawn from the study.These results support the use of reslizumab in patients with asthma and elevated blood eosinophil counts who are inadequately controlled on inhaled corticosteroid-based therapy.Teva Branded Pharmaceutical Products R&D.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
syx完成签到,获得积分20
刚刚
syvshc的应助被crazycathaha采纳,获得10
刚刚
凡夫俗女的应助被crazycathaha采纳,获得10
1秒前
syvshc的应助被crazycathaha采纳,获得10
1秒前
zero完成签到,获得积分10
1秒前
张伟发布了新的文献求助10
2秒前
3秒前
桃不掉了完成签到 ,获得积分10
4秒前
桐桐的应助被科研通管家采纳,获得10
4秒前
汉堡包的应助被科研通管家采纳,获得10
4秒前
4秒前
超级无敌的应助被科研通管家采纳,获得10
4秒前
syx发布了新的文献求助10
4秒前
Akim的应助被科研通管家采纳,获得10
4秒前
丘比特的应助被科研通管家采纳,获得10
5秒前
5秒前
5秒前
星辰大海的应助被科研通管家采纳,获得30
5秒前
5秒前
超级无敌的应助被科研通管家采纳,获得10
5秒前
烟花的应助被风1采纳,获得10
5秒前
5秒前
5秒前
超级无敌的应助被科研通管家采纳,获得10
5秒前
秋风的应助被科研通管家采纳,获得20
6秒前
Jeremy完成签到,获得积分10
6秒前
Ava的应助被科研通管家采纳,获得10
6秒前
6秒前
孙笑川爱学习完成签到,获得积分10
7秒前
充电宝的应助被fengfeng采纳,获得10
7秒前
7秒前
苻莞完成签到,获得积分10
8秒前
乐乐1314完成签到,获得积分10
8秒前
刘刘发布了新的文献求助10
10秒前
orixero的应助被骑着上帝去流浪采纳,获得10
12秒前
思源的应助被胡萝卜卜采纳,获得10
12秒前
满眼皆星辰的应助被Merry采纳,获得10
12秒前
吴千千完成签到,获得积分10
12秒前
cobra1989完成签到,获得积分10
12秒前
ferritin完成签到 ,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191366
求助须知:如何正确求助?哪些是违规求助? 9578238
关于积分的说明 21857620
捐赠科研通 7790721
什么是DOI,文献DOI怎么找? 3436607
关于科研通互助平台的介绍 2560359
邀请新用户注册赠送积分活动 2483340